4 Healthcare Stock Stories for the Well-Being of Investors

Eli Lilly and Company (NYSE:LLY): Current price $52.88

Lilly and its wholly owned subsidiary Avid Radiopharmaceuticals, said late Tuesday that Amyvid (Florbetapir F 18 Injection) has received European Commission marketing authorization as a diagnostic radiopharmaceutical that is indicated for Positron Emission Tomography imaging of beta-amyloid neuritic plaque density in the brains of adult patients suffering from cognitive impairment who are being studied for Alzheimer’s disease and other causes of cognitive impairment. In is noted that Amyvid should be used in conjunction with a clinical evaluation.